JATT II Acquisition Corp. (JATT)
| Market Cap | 93.60M |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 7.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,404 |
| Open | 12.00 |
| Previous Close | 12.01 |
| Day's Range | 12.00 - 12.25 |
| 52-Week Range | 9.99 - 23.76 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About JATT
JATT II Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in healthcare and healthcare-related businesses. The company was incorporated in 2026 and is based in Westfield, New Jersey.
News
Jatt II Acquisition Corp trading resumes
09:46 EDT Jatt II Acquisition (JATT) Corp trading resumes
Jatt II Acquisition Corp trading halted, volatility trading pause
09:41 EDT Jatt II Acquisition (JATT) Corp trading halted, volatility trading pause
JATT II Acquisition Corp Ordinary Shares trading resumes
09:37 EDT JATT II Acquisition (JATT) Corp Ordinary Shares trading resumes
JATT II Acquisition Corp Ordinary Shares trading halted, volatility trading pause
09:32 EDT JATT II Acquisition (JATT) Corp Ordinary Shares trading halted, volatility trading pause
JATT II Acquisition, Talawar Therapeutics announce combination agreement
Talawar Tx and JATT II Acquisition (JATT) Corp announced they have entered into a definitive business combination agreement. The combined company will operate as Talawar Therapeutics and is expected t...
JATT II's Biotech SPAC Debut: Sponsor's Varied History Faces a Doubtful Market
JATT II Acquisition: A New SPAC Targeting Biotech JATT II Acquisition, a newly formed blank check company focused on the biotech and life sciences sectors, | Bitget crypto news!
JATT II Acquisition IPO Registration Document (S-1)
JATT II Acquisition has filed to go public with an IPO on the NASDAQ
SPAC JATT II Acquisition files for a $60 million IPO, targeting biotech and life sciences
JATT II Acquisition, a blank check company targeting biotechs and life sciences businesses, filed on Friday with the SEC to raise up to $60 million in an initial public offering.